儿童IgA血管炎相关肾炎免疫抑制治疗结局
该研究回顾性分析了2005至2019年间来自25个国家41个儿科肾脏中心的1148例经活检证实的儿童IgA血管炎相关肾炎(IgAVN)患者,旨在描述临床表现、治疗及结局并识别预后风险因素。中位随访3.7年,末次随访时29%患者eGFR低于90 mL/min/1.73 m²,36%有蛋白尿,3%为CKD 4-5期。未发现任何特定二线免疫抑制方案优于其他方案,延迟开始免疫抑制治疗与末次随访时较低eGFR相关。
要点
- 年龄较大、起病时eGFR较低、高血压及肾小管萎缩和节段性硬化是预后不良的预测因素。
- 无证据支持任何特定二线免疫抑制方案优于其他方案,即使在肾功能下降、肾病综合征或低白蛋白血症亚组中。
- 延迟开始免疫抑制治疗与末次随访时eGFR较低相关。
核心结论
- 在该大型回顾性队列中,强调了与疾病结局相关的关键特征,但无证据支持任何特定免疫抑制治疗优于其他治疗。
研究设计与样本
- 回顾性收集2005至2019年间来自25个国家41个国际儿科肾脏中心的1148例经活检证实的IgAVN儿童数据,采用多变量分析。
主要发现
- 中位随访3.7年(四分位距2-6.2年)。
- 末次随访时29%患者eGFR低于90 mL/min/1.73 m²,36%有蛋白尿,3%为CKD 4-5期。
- 年龄较大、起病时eGFR较低、高血压及组织学肾小管萎缩和节段性硬化是预后不良的预测因素。
- 无证据支持任何特定二线免疫抑制方案优于其他方案,即使在肾功能下降、肾病综合征或起病时低白蛋白血症的亚组中。
- 延迟开始免疫抑制治疗与末次随访时eGFR较低相关。
临床怎么用
- 对具有预后不良因素(年龄较大、起病时eGFR较低、高血压、肾小管萎缩和节段性硬化)的IgAVN患儿应加强监测。
- 避免延迟开始免疫抑制治疗,因延迟与末次随访时eGFR较低相关。
- 选择二线免疫抑制方案时,当前证据未显示特定方案优于其他方案,需个体化决策。
局限性
- 回顾性研究设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunoglobulin A vasculitis with nephritis (IgAVN) is the most common vasculitis in children. Due to a lack of evidence, treatment recommendations are based on expert opinion, resulting in variation. The aim of this study was to describe the clinical presentation, treatment and outcome of an extremely large cohort of children with biopsy-proven IgAVN in order to identify prognostic risk factors and signals of treatment efficacy. METHODS: Retrospective data were collected on 1148 children with biopsy-proven IgAVN between 2005 and 2019 from 41 international paediatric nephrology centres across 25 countries and analysed using multivariate analysis. The primary outcome was estimated glomerular filtration rate (eGFR) and persistent proteinuria at last follow-up. RESULTS: The median follow-up was 3.7 years (interquartile range 2-6.2). At last follow-up, 29% of patients had an eGFR <90 mL/min/1.73 m2, 36% had proteinuria and 3% had chronic kidney disease stage 4-5. Older age, lower eGFR at onset, hypertension and histological features of tubular atrophy and segmental sclerosis were predictors of poor outcome. There was no evidence to support any specific second-line immunosuppressive regimen being superior to others, even when further analysing subgroups of children with reduced kidney function, nephrotic syndrome or hypoalbuminemia at onset. Delayed start of immunosuppressive treatment was associated with a lower eGFR at last follow-up. CONCLUSION: In this large retrospective cohort, key features associated with disease outcome are highlighted. Importantly, there was no evidence to support that any specific immunosuppressive treatments were superior to others. Further discovery science and well-conducted clinical trials are needed to define accurate treatment and improve outcomes of IgAVN.
引用
- Rohner K, Marlais M, Ahn YH, et al. Outcome of immunosuppression in children with IgA vasculitis-related nephritis. Nephrol Dial Transplant. 2024. PMID: 38211969. doi:10.1093/ndt/gfae009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。